Last reviewed · How we verify
NCT05526300
Intelligent Hypertension Intervention Study
NA trial testing Intelligent Hypertension Management System in To Explore Whether the Application of Intelligent Hypertension Management System Can Effectively Reduce Blood Pressure in Hypertensive Patients in 320 participants. Completed in 1 December 2024.
1 December 2024
Quick facts
| Lead sponsor | Shanghai Tong Ren Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 320 |
| Start date | 6 September 2022 |
| Primary completion | 1 December 2024 |
| Estimated completion | 1 December 2024 |
| Sites | 3 locations across China |
Drugs / interventions tested
- Intelligent Hypertension Management System
- The standard care
Conditions studied
- To Explore Whether the Application of Intelligent Hypertension Management System Can Effectively Reduce Blood Pressure in Hypertensive Patients — all drugs for To Explore Whether the Application of Intelligent Hypertension Management System Can Effectively Reduce Blood Pressure in Hypertensive Patients →
Sponsor
Shanghai Tong Ren Hospital
Who can join
Adults 18 to 75, any sex, with To Explore Whether the Application of Intelligent Hypertension Management System Can Effectively Reduce Blood Pressure in Hypertensive Patients. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To explore whether the application of intelligent hypertension management system can effectively reduce blood pressure in hypertensive patients. A total of 320 eligible subjects will be recruited and randomization to two groups. The standard care group (n=160) will receive conventional hypertension treatment with baseline data collected.Wearable blood pressure monitoring device management group (intervention group, n=160) will receive blood pressure monitoring remotely everyday and antihypertension medication treatment. Primary outcome is Net change in systolic blood pressure from baseline to 3 months follow-up. Secondary outcomes include Net change in diastolic blood pressure hypertension control ratio (BP \< 140/90 mmHg)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of intelligent hypertension management system on blood pressure: protocol for a randomised controlled multicentre trial.
Yu H, Chen X, Xia J, Hou L. · · 2023 · PMID 38086588 · DOI 10.1136/bmjopen-2023-074580
Verify or expand the search:
- PubMed search for NCT05526300
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Shanghai Tong Ren Hospital trials
Trials by the same sponsor.
- NCT06583564 — The Prognosis Effect of Indocyanine Green (ICG) Fluorescence Guided Surgery on Disease-free Survival (DFS) of Stage III · NA · not yet recruiting
- NCT06508541 — The Prognosis of Colorectal Cancer Patients After Indocyanine Green Fluorescence-guided Radical Surgery · completed
- NCT05736978 — Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results · Phase 2 · recruiting
- NCT05736965 — A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With A · Phase 2 · recruiting
- NCT06533124 — Parameters of Cardiac Indices on the Ultrasonic Cardiac Output Monitor As Potential Indicators for Predicting the Achiev · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05526300 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Tong Ren Hospital
- Last refreshed: 21 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05526300.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing